PMID- 19307958
OWN - NLM
STAT- MEDLINE
DCOM- 20091208
LR  - 20181201
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 32
IP  - 2
DP  - 2009 Apr
TI  - Phase II study of epirubicin in combination with weekly docetaxel for patients 
      with advanced NSCLC who have failed or relapsed after the frontline 
      platinum-based chemotherapy.
PG  - 169-73
LID - 10.1097/COC.0b013e31817eebdc [doi]
AB  - BACKGROUND: We conducted a phase II study to evaluate the efficacy and toxicity 
      of weekly docetaxel combined with epirubicin on D15 as second-line chemotherapy 
      in Taiwanese patients with advanced non small cell lung cancer (NSCLC) who failed 
      or relapsed after the frontline platinum-based chemotherapy. PATIENTS AND 
      METHODS: Patients with histologically confirmed advanced NSCLC (Stage IIIB-IV) 
      were entered into this Phase II trial. Eastern Cooperative Oncology Group 
      performance status was 0 to 2 and adequate organ function was required. 
      Docetaxel, 30 mg/m, was given intravenously on days 1, 8, and 15 for 30 minutes 
      and epirubicin, 60 mg/m, was given intravenously on day 15, then following one 
      week of rest. Treatment was repeated every 4 weeks for a maximal total of 6 
      cycles. RESULTS: Of the 43 eligible patients, 39 patients were evaluated for 
      response, and all were evaluated for toxicity. The overall response rate was 
      11.6% [95% confidence interval (CI), 1.6-21.6%]. The median time to disease 
      progression for all patients was 2.8 months (95% CI 1.3-4.3%). The median 
      survival time for all patients was 7.7 months (95% CI 5.5-9.9%). The 1-year 
      survival was 32.6% (95% CI 25.4%-39.7%). The major hematologic toxicities were 
      neutropenia, 8/43 (19%) with grade 3-4 neutropenia, as well as anemia, 6/43 (14%) 
      with grade 3-4 anemia. Nonhematological toxicities were modest. Fatigue was 
      common, 77.8% in all, but only 3 (7%) patients with grade 3-4 toxicities. 
      Diarrhea was also common but not severe, 7/43 (16%) with grade 1-2 episodes, and 
      1/43 (2%) with grade 3-4 episodes. Nail changes, peripheral edema, lacrimation, 
      and alopecia were mild. Hepatic and renal impairment was also only mild. 
      CONCLUSION: Combining weekly doses of docetaxel 30 mg/m with epirubicin 60 mg/m 
      on D15 was not shown to improve both efficacy and tolerability for advanced NSCLC 
      patients who have relapsed disease after frontline platinum-based chemotherapy.
FAU - Lin, Chih-Ming
AU  - Lin CM
AD  - Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan.
FAU - Chen, Chih-Hung
AU  - Chen CH
FAU - Chang, John W C
AU  - Chang JW
FAU - Tsao, Thomas C Y
AU  - Tsao TC
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - 3Z8479ZZ5X (Epirubicin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology
MH  - Docetaxel
MH  - Epirubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/diagnosis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Salvage Therapy
MH  - Survival Rate
MH  - Taxoids/administration & dosage
MH  - Treatment Failure
EDAT- 2009/03/25 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/03/25 09:00
PHST- 2009/03/25 09:00 [entrez]
PHST- 2009/03/25 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 00000421-200904000-00012 [pii]
AID - 10.1097/COC.0b013e31817eebdc [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2009 Apr;32(2):169-73. doi: 10.1097/COC.0b013e31817eebdc.